Generic Name and Formulations:
Lidocaine 5%; adhesive patch.
Indications for LIDODERM:
Apply to intact skin, covering most painful area. To adjust dose, cut patches before removing release liner. Remove if irritation or burning occurs; do not reapply until irritation subsides. May apply up to 3 patches at once for up to 12hrs of a 24-hour period. Hepatic impairment or debilitated: use smaller treatment areas.
Do not apply to broken or inflamed skin. Avoid eyes, mucous membranes, longer duration of application, and application of more than 3 patches. Do not ingest; may be toxic to children and pets. Hepatic disease. Small patients. Pregnancy (Cat.B). Labor & delivery. Nursing mothers.
Toxicity may be potentiated by Class I antiarrhythmics (e.g., tocainide, mexiletine). Additive effects with other local anesthetics.
Local effects (e.g., erythema, edema), allergic reactions (e.g., urticaria, angioedema, bronchospasm).
Patches (10cm x 14cm)—30
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D